Patent intelligence · AR
AR 120033
ANTAGONISTA RADIOMARCADO DE GRPR PARA USO COMO AGENTE TERAGNÓSTICO
ANTAGONISTA RADIOMARCADO DE GRPR PARA USO COMO AGENTE TERAGNÓSTICO
Patent details — AR 120033
- Jurisdiction
- AR
- Status
- granted
- Grant date
- Jan 26, 2022
- Expiration
- Jan 21, 2042
- CPC classes
- A61K 51/ 08 A I, A61K/51088, A61P 35/ 00 A I, A61P/3500
Quick answer
AR 120033 (ANTAGONISTA RADIOMARCADO DE GRPR PARA USO COMO AGENTE TERAGNÓSTICO) is held by ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT]. Status: granted. Granted Jan 26, 2022. Expires Jan 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 51/ 08 A I, A61K/51088, A61P 35/ 00 A I, A61P/3500
Frequently asked questions
What is US patent 120033?
AR 120033 (ANTAGONISTA RADIOMARCADO DE GRPR PARA USO COMO AGENTE TERAGNÓSTICO) is held by ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT]. Status: granted. Granted Jan 26, 2022. Expires Jan 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AR 120033?
ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews.
When does AR 120033 expire?
Our index shows an expiration date of Jan 21, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.